Q-omics provides the consensus-scored MIR139 profile across patient tissues and cancer cell-line models. MIR139 expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, MIR139 is differentially expressed in 2, with the highest sampling consensus in BRCA. Additionally, MIR139 RNA expression shows 4,676 significant gene co-expression associations, with the highest sampling consensus in SARC. Together, these results highlight KICH, BRCA, and SARC as cancer lineages where MIR139 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR139 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR139 survival associations across molecular data types. MIR139 RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR139 RNA expression–survival associations across cancer types. High MIR139 expression shows unfavorable associations in KICH, BLCA, CESC, UCEC, KIRC and LAML. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for MIR139 RNA expression.
This table summarizes MIR139 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR139. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR139 shows lower tumor expression in BRCA and LUSC. The BRCA box plot shows higher MIR139 RNA expression in normal versus tumor tissue (log2 FC = −0.041, t-test p = .025).
This table shows molecular features associated with MIR139 in patient tissues and cancer cell lines. In patient samples, MIR139 shows the broadest associations at the RNA and protein expression levels, with SARC recurring as the lineage with the largest associated feature set.
